Health ❯ Healthcare ❯ Pharmaceuticals

Cancer Treatment

Immunotherapy Breast Cancer Clinical Trials Bladder Cancer Multiple Myeloma Small Cell Lung Cancer Lung Cancer Pancreatic Cancer Prostate Cancer Mantle Cell Lymphoma

Pfizer Lung Cancer Drug Fails to Improve Survival in Late‑Stage Trial

The setback reduces near‑term prospects for the targeted antibody‑drug conjugate and shifts the program toward combination and earlier‑line studies.

GSK to Buy Nuvalent for $10.6 Billion to Bolster Lung‑Cancer Pipeline

New Oral Drug Nearly Doubles Survival for Treated Metastatic Pancreatic Cancer

Ivonescimab Extends Survival in China Phase 3 Trial for Squamous Lung Cancer

Study Finds Post-Diagnosis GLP-1 Use Linked to Lower Risk of Cancer Progression

Sacituzumab Tirumotecan With Keytruda Improves Progression-Free Survival in China Phase 3 Lung Cancer Trial

EMA Recommends Etcamah for ESR1‑Mutant Advanced Breast Cancer

FDA Accepts ImmunityBio Filing to Expand ANKTIVA Use in Bladder Cancer

Roche Launches 7-Minute Under-the-Skin Lung Cancer Shot in India

FDA Grants Accelerated Approval to First BCL2 Drug for Relapsed Mantle Cell Lymphoma

Abeona Posts $8.7 Million Q1 From ZEVASKYN as Patient Treatments and Sites Expand

FDA Approves Bizengri for NRG1 Fusion-Positive Cholangiocarcinoma

Novartis Breaks Ground on Texas Plant to Speed Radioligand Cancer Drug Delivery

FDA Authorizes Early Access to Daraxonrasib for Pancreatic Cancer Patients

Pfizer’s Elrexfio Posts Phase 3 PFS Win Over Standard Multiple Myeloma Regimen

Erasca Shares Plunge After Trial Death and Patent Challenge

Gilead Closes $7.8 Billion Arcellx Deal to Take Full Control of Anito‑cel

HHS Chief Distances From FDA Replimune Denial as Oncologists Dispute Review

EMA Validates Astellas Bid to Add Padcev–Keytruda Combo for Perioperative Muscle-Invasive Bladder Cancer

Dosing Disputes, Counterfeits, and a Patent Wall Put Keytruda Under Fresh Scrutiny